{"filings":[{"id":2530236,"accession_number":"0001539497-26-002373","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2026-08-28T12:01:39+00:00","items":["3.01"],"status":"ready","headline":"BioAtla faces Nasdaq delisting; trading to suspend Aug 31","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Listing Council affirmed delisting on Aug 26, 2026; suspension at open Aug 31, 2026.","Delisting due to bid price below $1.00 and failure to meet $2.5M stockholders' equity requirement.","Company expects OTC Markets quotation under ticker BCAB; liquidity and trading price may be materially affected.","Strategic review process initiated March 2026 to explore shareholder value alternatives remains ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-08-28","daily_digest_url":"/daily/2026-08-28","daily_digest_rank":3},{"id":1691836,"accession_number":"0001193125-26-306117","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2026-07-16T20:12:27+00:00","items":["5.07"],"status":"ready","headline":"BioAtla stockholders elect directors, ratify auditor, approve say-on-pay at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jay M. Short and Edward Williams elected as Class III directors with ~70% of votes cast (excluding broker non-votes).","Ernst & Young ratified as independent auditor for FY2026: 869,667 for, 18,545 against, 18,771 abstentions.","Non-binding advisory vote on executive compensation approved: 281,294 for, 96,492 against, 69,033 abstentions.","Approximately 55% of outstanding shares (906,983 shares) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95898,"accession_number":"0001193125-26-140053","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioAtla to effect 1-for-50 reverse stock split via merger effective April 6, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Certificate of Merger filed April 2, 2026; merger effective April 6, 2026 at 12:01 a.m. Eastern Time.","Every 50 outstanding shares of common stock will be converted into 1 share.","Merger with wholly owned subsidiary BA Merger Sub, Inc.; BioAtla is the surviving corporation.","No change to company name or business; charter remains as in effect prior to merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109316,"accession_number":"0001193125-26-134501","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioAtla initiates strategic review to monetize assets; Q4 net loss $9.8M, cash $7.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board launched formal process to explore sale, licensing, or other strategic options; Tungsten Advisors engaged.","Net loss Q4 2025: $9.8M versus $14.9M year ago; full year net loss $59.6M.","Cash and equivalents $7.1M at Dec 31, 2025; company expects to extend runway via cost cuts and equity facility.","March 2026 workforce reduction implemented; re-evaluating Phase 1 BA3182 enrollment and Phase 3 ozuriftamab vedotin timeline.","Pre-paid advance agreements fully converted to common stock; no remaining obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109315,"accession_number":"0001193125-26-119698","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"BioAtla shareholders approve 1-for-50 reverse stock split merger; executive retention bonuses set","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Merger and Share Consolidation (1:50 reverse split) on March 23, 2026; 49.2M votes for, 1.47M against.","CEO Jay Short retention bonus target $449,712 (60% salary) tied to milestones by Aug 31, 2026.","CFO Christian Vasquez retention bonus target $186,110 total; CMO Eric Sievers $265,315 total, both split across May and Aug milestones.","No salary increases for 2026; no 2025 bonuses earned as financial milestones were missed.","Bonuses subject to sliding scale (80%-120% of target); employment required through payout."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109314,"accession_number":"0001539497-26-000812","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","7.01","2.05","5.02","8.01","9.01"],"status":"ready","headline":"BioAtla initiates strategic review, cuts 70% workforce; CFO replaced; cash ~$7.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduced ~70%; severance costs estimated $0.5-0.6M; committed Feb 24, 2026.","CFO Richard Waldron departs March 2; succeeded by Chief Accounting Officer Chris Vasquez.","Formal strategic review launched to monetize assets; Tungsten Advisors engaged as advisor.","Preliminary cash and cash equivalents $7.1M as of Dec 31, 2025; no PPA amounts outstanding.","Nasdaq delisting review ongoing; $40M SPV transaction with Inversagen AI not yet closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109313,"accession_number":"0001193125-26-041852","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq Listing Council stays BCAB delisting, calls review of Feb 6 non-compliance determination","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq determined Feb 6 to delist BCAB for non-compliance with bid price ($1) and stockholders' equity ($2.5M) requirements.","On Feb 8, Nasdaq Listing Council called review of delist decision and stayed suspension; BCAB continues trading on Nasdaq.","Company asserts Nasdaq's delay and policy change on super-voting stock caused irreparable harm.","Listing Council review may take weeks to months; no assurance stock will remain listed after review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109312,"accession_number":"0001193125-26-041367","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["3.01","7.01"],"status":"ready","headline":"BioAtla receives Nasdaq delisting notice; trading suspension effective Feb 10","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel determined to suspend BCAB common stock at open on Feb 10, 2026 for non-compliance with $1.00 bid price and $2.5M stockholders' equity requirements.","Company requested immediate review and stay by Listing Council; Nasdaq counsel refused, but company claims precedent exists for such stays.","If suspended, BCAB is expected to trade on OTC under same symbol, which may materially affect trading price and volume.","As of Feb 6, $1.25M principal remained outstanding under Pre-Paid Advance Agreements; SEPA prohibits share sales during suspension.","Company asserts Nasdaq improperly delayed compliance confirmation and secretly overturned long-standing reverse stock split policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109311,"accession_number":"0001193125-26-031942","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["5.03","5.07","7.01","8.01","9.01"],"status":"ready","headline":"BioAtla adopts 1-for-50 reverse stock split via merger after Nasdaq policy reversal; delisting risk","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued one share of super-voting Series A Preferred to pass reverse split (100M votes for), then redeemed it for $0.01.","Board chose not to implement reverse split; Nasdaq said super-voting use now violates Rule 5640 without public notice.","Entered merger for 1-for-50 reverse split; requires majority stockholder vote at special meeting.","AIRC confirmed investment in Inversagen AI; BioAtla to receive $5M for 4.375% of SPV common units.","Nasdaq compliance deadline Feb 2; company believes Nasdaq's delays and policy change were in error and harmful."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109310,"accession_number":"0001193125-26-010458","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["3.02","5.03","5.07","8.01","9.01"],"status":"ready","headline":"BioAtla issues super-voting share to CEO; reverse stock split vote fails, adjourned to Jan 26","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued one share of Series A Junior Preferred Stock to CEO Jay Short for $0.01, granting vote power equal to outstanding common shares on reverse split proposals.","At Jan 12, 2026 special meeting, reverse stock split proposal failed to reach required two-thirds vote; meeting adjourned to Jan 26 for additional proxy solicitation.","Over 70% of proxies received were FOR the reverse split, but insufficient to meet two-thirds of outstanding voting power.","Super-Voting Share will automatically vote FOR the reverse split if two-thirds of common shares present vote FOR; else votes AGAINST.","Board set new record date of Jan 12, 2026 for the reconvened meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125800,"accession_number":"0001193125-25-337646","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"BioAtla enters $40M SPV deal to advance Oz-V Phase 3; retains 65% ownership","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total $40M from Inversagen AI for 35% of SPV units; initial $5M closing by Jan 30, 2026.","BioAtla retains 65% ownership of Oz-V across all solid tumor indications after transaction.","Proceeds fund Phase 3 trial for Oz-V in 2L+ OPSCC; enrollment expected to begin early 2026.","Related-party transaction: Chairman/CEO Dr. Jay Short and spouse are managers of Inversagen entities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125799,"accession_number":"0001193125-25-337078","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"BioAtla special meeting adjourned; reverse stock split proposal lacks sufficient votes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 (issuance of common stock under pre-paid advance agreements) passed: 19.8M for, 9.4M against.","Proposal 2 (reverse stock split at 1:5 to 1:20 ratio) failed to secure enough votes; meeting adjourned to Jan 12, 2026.","Proposal 3 (adjournment) approved with 30.0M for, 8.9M against.","Record date stockholders can attend virtual reconvened meeting on Jan 12, 2026 at 8:30 a.m. PT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125798,"accession_number":"0001193125-25-290474","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"BioAtla raises $7.5M via PPAs and $15M SEPA; Yorkville gets 243,428 commitment shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["PPAs for $7.5M face amount; net proceeds ~$7.13M at 95% of face; due in 12 months.","PPA conversion price is lower of 115% of prior VWAP or 95% of lowest 7-day VWAP, with floor at 20% of closing price.","SEPA allows BioAtla to sell up to $15M common stock to Yorkville over 36 months at 97% of lowest 3-day VWAP.","Yorkville received 243,428 commitment shares worth $300,000 as SEPA fee.","Company restricts other variable-rate transactions until PPA repaid; 19.99% Exchange Cap may limit total shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125797,"accession_number":"0001193125-25-280141","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioAtla Q3 net loss $15.8M; FDA aligns on Phase 3 Oz-V design; partnership on track by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 net loss $15.8M vs $10.6M in 2024 (which included $11M Context collaboration revenue); cash $8.3M at Sept 30.","FDA alignment achieved on Phase 3 Oz-V trial for 2L+ OPSCC; dual primary endpoints (ORR and OS) with potential accelerated approval.","Company in advanced stages to finalize a strategic transaction by year-end; Context milestone payment of $2M received.","BA3182 (CAB-EpCAM x CD3 TCE) Phase 1 dose escalation ongoing; readout expected in first half 2026.","R&D expenses decreased to $9.5M from $16.4M due to program prioritization and workforce reduction in March 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142530,"accession_number":"0001193125-25-211305","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioAtla granted Nasdaq continued listing with conditions through Feb 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Panel approved continued listing pending transfer to Capital Market by Sept 26, 2025 (filed Sept 18).","Must demonstrate compliance with Minimum Stockholders' Equity Requirement by Dec 31, 2025.","Must demonstrate compliance with Minimum Bid Price Requirement by Feb 2, 2026.","Company believes it can meet both deadlines but provides no assurance.","Previously disclosed delisting risk from failure to meet bid price and equity requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142529,"accession_number":"0000950170-25-105000","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioAtla Q2 net loss $18.7M; cash $18.2M; Oz-V 45% ORR in HPV+ OPSCC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.7M for Q2 2025 vs $21.1M in Q2 2024; R&D expense down to $13.7M.","Cash and cash equivalents $18.2M as of June 30, 2025, down from $49.0M at Dec 31, 2024.","BA3182 (EpCAM x CD3 TCE) Phase 1 dose-escalation ongoing; data readout expected 2H 2025.","Oz-V (CAB-ROR2-ADC) shows 45% ORR (5/11) in 2L+ HPV+ OPSCC; FDA meeting planned in 3Q 2025.","Company advancing partnering discussions; confident in closing at least one transaction in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160575,"accession_number":"0000950170-25-088499","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"BioAtla sets 2025 bonus targets, elects directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["2025 Bonus Plan approved: CEO target 60% of base, CFO 40%, CMO 40%; payout 50%-125%.","Corporate goals: clinical milestones 25%, financing 50%, financial/people 20%, brand awareness 5%.","Annual meeting elected directors Gray, Moran, Steinman; ratified Ernst & Young as auditor (30.2M for).","Say-on-pay non-binding vote passed with 8.96M for vs 4.49M against; 52% of shares voted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160574,"accession_number":"0000950170-25-073688","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BioAtla receives Nasdaq delisting notice for failing $10M equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity was $547K as of March 31, 2025, far below the $10M minimum for Nasdaq Global Market.","Company has until June 26, 2025 to submit a compliance plan; Nasdaq may grant a 180-day extension.","No immediate delisting effect; company intends to submit plan and take reasonable measures to regain compliance.","Also failed alternative compliance standards based on market value of listed securities or total assets and revenue.","Risk of delisting persists if plan is not accepted or compliance not regained within any granted period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160573,"accession_number":"0000950170-25-064415","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioAtla Q1 net loss $15.3M; cash $32.4M; Mec-V shows 59% 2-year OS in mKRAS NSCLC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.3M vs $23.2M YoY; R&D expenses down to $12.4M from $18.9M.","Cash $32.4M at March 31, 2025; expects runway beyond key readouts in 1H 2026.","BA3182 Phase 1 dose-escalation ongoing; data readout mid-2025; three patients dosed at 300 µg.","Mec-V in mKRAS NSCLC shows 67% 1-year and 59% 2-year landmark OS (SOC <20%).","Oz-V in HPV+ SCCHN: 45% ORR (5/11), 100% disease control; Fast Track discussions with FDA."],"consensus_eps_estimate":-17.6802,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178819,"accession_number":"0000950170-25-046065","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"BioAtla reports Q4 net loss $14.9M, cuts workforce 30% to extend runway to 1H 2026 clinical readouts","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $14.9M in Q4 2024 vs $26.9M Q4 2023; cash $49.0M at year-end vs $111.5M.","Workforce reduction of over 30%; estimated $0.5-$0.6M in severance costs mostly in Q2 2025.","BA3182 (CAB-EpCAM x CAB-CD3) Phase 1 dose escalation ongoing; data readout mid-2025; expansion data 1H 2026.","Mecbotamab vedotin (CAB-AXL-ADC): 66% 1-year OS, 58% 2-year OS in mKRAS NSCLC; median OS not reached.","Ozuriftamab vedotin (CAB-ROR2-ADC): 45% ORR (confirmed/unconfirmed) in HPV+ SCCHN; partnering discussions Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178818,"accession_number":"0000950170-25-039400","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioAtla awards cash bonuses and RSUs to CEO, CFO, and CMO for 2024 performance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Jay Short receives $275,558 cash bonus (62.5% of target) and 431,000 RSUs.","CFO Richard Waldron receives $120,160 cash bonus (62.5% of target) and 100,000 RSUs.","CMO Eric Sievers receives $127,555 cash bonus (62.5% of target) and 175,000 RSUs.","RSUs vest 25% after one year, then 6.25% quarterly over 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178817,"accession_number":"0000950170-25-016321","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BioAtla receives Nasdaq notice of non-compliance with minimum bid price rule; 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Feb 6, 2025 for failing minimum bid price of $1.00 for 30 consecutive business days.","Company has 180 calendar days (until Aug 5, 2025) to regain compliance.","Compliance can be achieved by maintaining $1.00 closing bid for 10 consecutive business days.","Additional 180-day compliance period possible if transferred to Nasdaq Capital Market.","If not cured, common stock subject to delisting; company considering options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195494,"accession_number":"0001193125-24-283212","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"BioAtla raises $9.2M in registered direct offering to fund mid-stage TCE and ADC programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 9,679,158 shares and accompanying warrants at $0.9520/unit; gross proceeds ~$9.2M.","Warrants exercisable at $1.19/share for 5.5 years, beginning 6 months after issuance.","Proceeds to fund BA3182 Phase 1 dose escalation data (2Q25) and Phase 2 expansion data (1H26).","Proceeds also to fund mecbotamab vedotin Phase 2B data in mKRAS NSCLC (1H26).","Officers and directors subject to 75-day lock-up; company restricted on equity issuance for 75 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195493,"accession_number":"0001193125-24-282547","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioAtla updates corporate presentation; no specific details available in excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["BioAtla furnished an updated corporate presentation on December 20, 2024, for investor meetings.","The presentation title references 'Conditionally Active Biologics' but no clinical or financial data are shown in the provided excerpt.","Without the full presentation content, no material new information can be extracted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195492,"accession_number":"0000950170-24-123281","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioAtla Q3 net loss narrows to $10.6M on $11M collaboration revenue; cash runway into early 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $10.6M vs $33.3M in Q3 2023; R&D expenses fell to $16.4M from $28.4M.","Cash and equivalents $56.5M at Sept 30, 2024, down from $111.5M at Dec 31, 2023.","Ozuriftamab vedotin (CAB-ROR2-ADC) shows median OS ~9 months in heavily pretreated SCCHN; FDA supported pivotal trial design.","Evalstotug (CAB-CTLA-4) + PD-1 produced tumor reduction in all 8 first-line melanoma patients, with 1 CR and 3 PRs.","Worldwide license agreement for CAB-Nectin-4 TCE with Context Therapeutics for up to $133.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211752,"accession_number":"0001193125-24-223282","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BioAtla licenses Nectin-4 x CD3 bispecific antibody to Context Therapeutics for up to $133.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BioAtla grants exclusive worldwide license to Context for two antibodies including BA3362 (CT-202), a Nectin-4 x CD3 TCE bispecific.","BioAtla eligible for up to $133.5M total, including $15M upfront/near-term milestones and $118.5M in future milestones plus tiered royalties.","BioAtla enters Global Transaction Agreement with Himalaya Therapeutics, consenting to license and sharing a mid-teens percentage of upfront/milestone payments.","Context may terminate at will; BioAtla may terminate if Context halts development for 8 consecutive quarters.","BioAtla agrees to refrain from competitive activities regarding Nectin-4 bispecific/multi-specific antibodies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211751,"accession_number":"0000950170-24-093888","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioAtla Q2 net loss $21.1M; cash to Q3 2025; Fast Track for ozuriftamab vedotin","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.1M for Q2 2024 vs $35.8M in Q2 2023; R&D expenses fell to $16.2M from $31.0M.","Cash and equivalents $61.7M as of June 30, 2024, expected to fund operations through Q3 2025.","Ozuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track by FDA for SCCHN; FDA meeting for registrational trial expected in 2H 2024.","Mecbotamab vedotin (CAB-AXL-ADC) Phase 2 in NSCLC shows OS trend in mutated KRAS; responses across G12A, G12C, G12V.","Evalstotug (CAB-CTLA-4) combined Phase 1/2 safety: low grade 3 irAEs (4/40); Phase 2 melanoma data on track for 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230502,"accession_number":"0000950170-24-073139","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioAtla annual meeting elects director, ratifies auditor, approves say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected Sylvia McBrinn as Class I director with 15,280,856 votes for and 7,634,075 withheld; broker non-votes 11,599,001.","Ratified Ernst & Young LLP as auditor for FY2024 with 34,271,982 votes for, 106,553 against, 135,397 abstentions.","Non-binding advisory vote on executive compensation passed with 17,643,438 votes for, 5,121,016 against, and 153,387 abstentions.","Approximately 71.75% of outstanding shares (34,513,932) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230501,"accession_number":"0000950170-24-061616","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioAtla settles shareholder derivative suit, pays $350K in fees after bylaw reforms","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Company paid $350,000 in attorneys' fees to settle claims over bylaw amendments imposing disclosure requirements on dissident director nominations.","BioAtla amended bylaws on April 22, 2024, to address challenged provisions; company denies all wrongdoing.","Delaware Court of Chancery closed the action on May 15, 2024, subject to filing notice to putative class.","Plaintiff alleged directors breached fiduciary duties by adopting bylaw amendments on January 5, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230500,"accession_number":"0000950170-24-059508","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioAtla Q1 net loss $23.2M, cash $80.6M; positive Phase 2 data for ozuriftamab vedotin and evalstotug","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.2M in Q1 2024 vs $27.5M in Q1 2023; cash $80.6M as of March 31, 2024.","Ozuriftamab vedotin in SCCHN: 11 total responses (5 confirmed incl. 1 CR), 86% DCR; FDA meeting for potential registrational trial expected 2H 2024.","Evalstotug: DLT clearance at 1 gram in 2Q 2024; Phase 2 monotherapy data 2Q 2024; FDA meeting for BRAF-mutated melanoma registrational trial in 2H 2024.","Mecbotamab vedotin in UPS: initial 20 patients enrolled; FDA meeting for remaining trial portion 2H 2024.","CAB-Nectin4-ADC (BA3361) received FDA IND clearance in May 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230499,"accession_number":"0000950170-24-047595","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"BioAtla amends advance notice bylaw for stockholder nominations","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Removed requirement to disclose if another person is Acting in Concert with a Proposing Person.","Clarified that stockholder notice must include names, addresses, and ownership of financial supporters.","Allowed stockholder to cure deficiencies in Timely Notice by the last day such notice may be delivered.","Removed requirement to respond within 7 business days to Company inquiries and to submit to interviews.","Modified definitions of 'Acting in Concert', 'Associated Person', and 'principal competitor'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248890,"accession_number":"0000950170-24-036395","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioAtla Q4 net loss $26.9M; cash $111.5M; multiple Phase 2 readouts on track for 2Q 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023: $26.9M vs $27.6M Q4 2022; R&D expense $22.7M vs $21.9M.","Cash $111.5M at year-end 2023; expected to fund operations into 2H 2025.","CAB-CTLA-4 (BA3071) cleared DLT at 700 mg; Phase 2 monotherapy data due 2Q 2024.","CAB-ROR2-ADC (BA3021) Phase 2 melanoma/SCCHN fully enrolled; data readouts in May.","CAB-AXL-ADC (BA3011) UPS registration trial enrollment ~20 patients due April; FDA meeting 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248889,"accession_number":"0000950170-24-017881","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioAtla awards 2023 cash bonuses and RSUs to executives; approves 2024 bonus plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Jay Short receives $419,491 cash bonus for 2023; CFO Waldron $184,718; CMO Sievers $184,338; CAO Vasquez $115,800.","Time-based RSU grants: 417,000 to Short, 106,000 to Waldron, 122,000 to Sievers, 70,000 to Vasquez; vest over 4 years.","Compensation Committee approved 2024 Corporate Bonus Plan; targets: CEO 60%, other officers 40% of base salary.","2024 bonus heavily weighted: 30% clinical milestones, 20% strategic partnerships, 20% financing, 10% R&D, 10% financial/people, 10% brand.","Vasquez promoted to CAO effective Jan 1, 2024; target bonus increased to 40% from 35%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248888,"accession_number":"0000950170-24-013807","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2024-02-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioAtla faces class action over advance notice bylaws; board waives challenged provisions for 2024 meeting","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Upendar Golla filed putative class action in Delaware Chancery on Feb 6, 2024 against BioAtla and its Board.","Lawsuit challenges certain advance notice bylaw provisions as invalid and alleges breach of fiduciary duties.","Board will not enforce challenged provisions for 2024 annual meeting, easing disclosure requirements for stockholders.","Company reserves right to waive compliance with any advance notice provisions for the meeting in its sole discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248887,"accession_number":"0001193125-24-004912","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioAtla updates corporate presentation for J.P. Morgan Healthcare Conference","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished updated corporate presentation for use at 42nd Annual J.P. Morgan Healthcare Conference.","Presentation includes pipeline and business strategy updates, but full content not detailed in filing.","No new financial guidance, material transactions, or leadership changes disclosed.","Confidence low due to truncated exhibit; no specific data points available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248886,"accession_number":"0001193125-24-004539","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"BioAtla amends bylaws to align with DGCL changes and add universal proxy rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amended and restated bylaws on Jan 5, 2024; effective immediately.","Revised advance notice procedures, restricts nominee count, and requires compliance with Rule 14a-19.","Added emergency bylaw provision, electronic notice updates, and proxy card color rule for stockholder solicitations.","Ministerial and clarifying changes to conform to DGCL and SEC regulations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266423,"accession_number":"0001193125-23-293959","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BioAtla reports Phase 1 data for BA3071: confirmed responses in solid tumors, safe profile, Phase 2 initiated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 dose-escalation of BA3071 (CAB-CTLA-4) in 18 PD-1-failure patients: 2 confirmed responses (1 CR stage IV cervical, 1 PR stage IV gastro-esophageal), 9 stable disease.","No grade 4 treatment-emergent adverse events; two grade 3 immune-related AEs. Maximum tolerated dose not reached; DLT at 700 mg.","Durable disease control: uveal melanoma (>12 cycles), cutaneous melanoma (>14, >17 cycles), SCLC (>22 cycles).","Phase 2 monotherapy and in combination with PD-1 inhibitor is now underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266422,"accession_number":"0001193125-23-288019","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2023-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioAtla holds KOL event on BA3011 Phase 2 NSCLC data; no specific results given","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["KOL event on Dec 4 featured Dr. Carl M. Gay (MD Anderson) discussing BA3011 (CAB-AXL-ADC) Phase 2 data in refractory NSCLC.","Select slides from the presentation filed as Exhibit 99.1; no detailed efficacy or safety numbers provided in the filing.","Company reiterates forward-looking statements; no guidance or material changes announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266421,"accession_number":"0000950170-23-060210","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioAtla Q3 net loss $33.3M; FDA backs registrational path for BA3011 in NSCLC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $33.3M in Q3 2023 from $25.8M a year ago, driven by a 43% rise in R&D costs.","Cash fell to $141.3M at Sep 30, down from $215.5M at Dec 31 2022; now expected to fund operations into 2H 2025.","FDA supportive of registrational path for CAB-AXL-ADC (BA3011) in NSCLC; detailed Phase 2 data to be presented in early December.","New partial responses observed with CAB-ROR2-ADC (BA3021) in melanoma and head & neck cancer at Phase 2.","Phase 2 for CAB-CTLA-4 (BA3071) initiated with first patient in; Phase 1 data and R&D Day on Dec 13."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283657,"accession_number":"0000950170-23-036440","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioAtla reports Q2 2023 net loss of $35.8M; cash $168.7M funds into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $35.8M for Q2 2023 vs $28.9M in Q2 2022; R&D expenses rose to $31.0M from $20.7M.","Cash at June 30, 2023 was $168.7M, down from $215.5M at Dec 31, 2022; expected to fund operations into 2025.","Phase 2 potentially registrational BA3011 UPS study continues enrolling; FDA meeting request submitted for NSCLC study.","CAB-CTLA-4 BA3071 cleared fifth cohort (5 mg/kg) with no DLTs; sixth cohort enrolling; Phase 1 data readout on track for 2H23.","Anticipated data across BA3021 NSCLC, melanoma, SCCHN to enable 'go' decision for indications in 2H23."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303180,"accession_number":"0000950170-23-028007","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioAtla stockholders elect three Class III directors at June 14, 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three director nominees (Short, Smith, Williams) elected with ~79% votes for excluding broker non-votes.","Ratification of Ernst & Young as auditor for FY2023 passed with over 36.5M votes for.","Non-binding advisory vote on executive compensation approved with ~27.5M for, ~1.4M against.","78.31% of outstanding shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303179,"accession_number":"0000950170-23-021212","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioAtla Q1 net loss $27.5M; cash $192.7M funds operations into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $192.7M as of March 31, 2023, down from $215.5M at Dec 31, 2022.","Net loss $27.5M vs $24.3M in Q1 2022; R&D expense rose to $21.7M from $16.9M.","Phase 2 potentially registrational BA3011 UPS study enrolling; LMS cohort readout expected 2H23.","FDA meeting request for BA3011 NSCLC Phase 2 part 2 on track for 1H23; initiation in 2H23.","BA3021 NSCLC interim readout and BA3071 Phase 1 data readout both on track for 2H23."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322820,"accession_number":"0000950170-23-009469","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioAtla reports FY2022 net loss $106.5M, cash $215.5M; advances CAB-ADC and bispecific trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2022 $27.5M, full year $106.5M, vs Q4 2021 $23.4M and FY2021 $95.4M.","R&D expenses FY2022 $79.3M, up from $58.3M in FY2021, driven by clinical development.","Cash $215.5M at year-end 2022; expected to fund operations into 2025.","Cleared DLT for BA3011 dose-intensive schedule; LMS readout 2H23; UPS registrational Phase 2 start in 1H23.","FDA cleared IND for BA3182 (CAB-EpCAMxCD3 TCE); FPI Phase 1 in 1H23. BA3021 NSCLC and BA3071 Phase 2 data in 2H23."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322819,"accession_number":"0000950170-23-007213","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"BioAtla has no cash or securities at Silicon Valley Bank, no exposure to SVB collapse","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company confirms it does not hold deposits or securities at Silicon Valley Bank.","Disclosure comes in response to SVB's March 2023 failure affecting many biotech firms.","No financial impact from SVB closure; operations and cash position unaffected.","Investor concern about SVB exposure is addressed with this Regulation FD disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322818,"accession_number":"0001193125-23-049760","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioAtla President Scott Smith resigns to become Viatris CEO; remains on board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Smith resigns as President effective Feb 27, 2023 to become CEO of Viatris (Nasdaq: VTRS).","Smith will continue to serve as a director on BioAtla's board of directors.","His equity awards will continue to vest based on continued board service.","Jay M. Short remains Chairman and CEO of BioAtla."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322817,"accession_number":"0000950170-23-002910","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2023-02-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioAtla awards 2022 cash bonuses to executives, approves 2023 Bonus Plan","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Jay Short awarded $370,429 cash bonus for 2022, reflecting 90% of target.","CFO Richard Waldron received $163,116; CMO Eric Sievers $160,618; President Scott Smith $257,522; SVP Finance Vasquez $90,345.","Christian Vasquez promoted to SVP of Finance; target bonus increased from 30% to 35% of salary.","2023 Bonus Plan ties executive bonuses to clinical milestones (45%), R&D (20%), strategic (20%), brand (15%).","Payouts range from 50% to 125% of target; threshold is 50% weighted performance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322816,"accession_number":"0001193125-23-003550","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2023-01-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BioAtla enters $100M ATM equity offering with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $100M aggregate gross sales proceeds from common stock sold through Jefferies as sales agent.","Jefferies will receive 3% commission on gross proceeds; company reimburses certain expenses.","Company has no obligation to sell shares; may suspend offering at any time.","Shares issued under existing effective shelf registration statement (File No. 333-262528).","Offering terminates upon sale of all shares or termination of agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340882,"accession_number":"0001193125-22-279214","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BioAtla enters underwriting agreement to sell 9.745M shares at $6.67/share for $65M gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 9,745,128 common shares at $6.67 each; gross proceeds $65M before discounts and expenses.","Underwriter J.P. Morgan Securities LLC; closing expected Nov 8, 2022 subject to customary conditions.","Offering made under Form S-3 shelf registration (File 333-262528) declared effective May 18, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340881,"accession_number":"0001193125-22-277328","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2022-11-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioAtla reports 36% ORR in NSCLC and meets Go criteria in multiple sarcoma subtypes for BA3011","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NSCLC Phase 2 Part 1: ORR 36% (5/14), 42% in non-squamous (5/12); 1 CR and 4 PRs.","Sarcoma: Go criteria met for UPS, osteosarcoma, liposarcoma, and synovial sarcoma into Part 2.","UPS (Phase 1&2, n=10): ORR 50% (4/8 evaluable), 3-month PFS rate 50%, median PFS 6.8 months.","Osteosarcoma (n=6): 3-month PFS rate 66.7%; liposarcoma (n=6): 66.7%; synovial sarcoma (n=5): 54%.","FDA supportive of proposed registrational Part 2 study in UPS (n=80, primary endpoint ORR); enrollment expected by year-end 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340880,"accession_number":"0000950170-22-021833","cik":1826892,"company_name":"BioAtla, Inc.","ticker":"BCAB","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioAtla reports Q3 net loss $25.8M; cash $178.1M; BA3011 NSCLC shows 50% ORR in monotherapy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $178.1M as of Sep 30, 2022, expected to fund operations into 2H24.","Net loss $25.8M for Q3 2022 vs $22.9M in Q3 2021; R&D expense increased to $19.8M.","BA3011 Phase 2 NSCLC: 4 PRs in monotherapy (ORR 50%) in non-squamous group; 1 CR in combination.","BA3011 UPS part 2 enrollment anticipated to start by year-end after FDA feedback; potential registrational path.","BA3071 Phase 1: first two cohorts completed without DLTs or SAEs; BA3182 IND on track by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5981502.879356569,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-03T23:59:59+00:00|340880"}